ams provides sensor technology for medical technology startup midge medical to develop rapid test device for COVID-19 (SARS-CoV-2)

(PresseBox) ( Premstaetten, )
News facts:
  • Rapid test results will be available in as little as 15 minutes
  • Miniaturization of genetic amplification technique enables implementation of effective test
    strategies at a reduced cost, both at home and in professional healthcare environments
  • ams AS7341L spectral sensor allows reliable spectrally resolved read out of virus particles
ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, provides the latest sensor technology to midge medical, a German medical technology startup from Berlin, to develop a disruptive technology for science-backed rapid genetic and blood testing in a home and professional healthcare environment at a lower cost. midge medical’s current focus is on developing a pocket-sized COVID-19 (SARS-CoV-2) genetic test. Test results can be read-out using a smartphone in as little as 15 minutes. ams and midge medical’s collaboration aims to provide a technology with the potential to move the current market forward.
A specifically developed sensor system based on the ams AS7341L spectral sensor solution allows spectrally resolved read out of amplified COVID-19 (SARS-CoV-2) virus particles, strengthening ams’ position in delivering high-quality consumer health diagnostics.

Helping fight the COVID-19 (SARS-CoV-2) pandemic

The current COVID-19 (SARS-CoV-2) crisis has made it clear: experts suggest there is an urgent need for frequent high-quality testing of symptomatic and asymptomatic people to manage the current pandemic and future crises. The new test addresses the unmet need of frequent, affordable, rapid and mass testing during the pandemic.

A promising cooperation

“The unique diagnostic vision of midge medical, in combination with ams’ highly-performant and sensitive spectral sensors, has resulted in a miniaturized readout at a fraction of the cost of currently available systems, enabling decentralized testing at home and in professional healthcare environments. The midge smartphone app delivers instant results that can be displayed on any authorized smartphone,” said Jennifer Zhao, Executive Vice President for Advanced Optical Sensors Division at ams.

“We are pleased to collaborate with ams as a globally known strong partner to bring this low cost type of test to the market. By enabling broad and frequent testing, even in the absence of immunization, going back to an almost normal life will be possible again,” added Michael Diebold, CEO at midge medical.

For more information on the ams AS7341L spectral sensor, please visit

About ams

ams is a global leader in the design and manufacture of advanced sensor solutions. Our mission is to shape the world with sensor solutions by providing a seamless interface between humans and technology.

ams’ high-performance sensor solutions drive applications requiring small form factor, low power, highest sensitivity and multi-sensor integration. Products include sensor solutions, sensor ICs, interfaces and related software for consumer, communications, industrial, medical, and automotive markets.

With headquarters in Austria, ams employs around 9,000 people globally and serves more than 8,000 customers worldwide. ams is listed on the SIX Swiss Exchange (ticker symbol: AMS). More information about ams can be found at

ams is a registered trademark of ams AG. In addition, many of our products and services are registered or filed trademarks of ams Group. All other company or product names mentioned herein may be trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.

Join ams social media channels:

>Twitter  >LinkedIn   >Facebook   >YouTube

About midge medical

Founded 2016 to fight antibiotic resistance, our integrated Point-of-Need platforms are designed for earlier detection of infections and diseases, more precise and faster diagnoses, and personalized therapies for the chronically ill based on regular testing. More information on
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an